Differences in Ovarian Aging Between Caucasian and Indian Women

Ethnicity as a Determinant of Ovarian Aging: Differences Between Caucasian and Indian Women

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02210013

Enrollment

400

Registered

2014-08-06

Start date

2012-01-31

Completion date

2013-01-31

Last updated

2014-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age of the Patients and the Body Mass Index in Both Groups

Keywords

AMH, AFC, aging, ethnicity

Brief summary

The investigators want to carry out a prospective study of 400 infertile Caucasian and Indian women who will undergo a controlled ovarian stimulation for in vitro fertilization (IVF). The investigators will collect data about ovarian reserve markers and also the results after ovarian stimulation in both ethnic groups.The aim is to identify differences in ovarian response after IVF stimulation between both groups.

Detailed description

A total of 200 Caucasian patients and 200 Indian patients who will attend the first or second IVF cycle will be included. The date we will collect in both groups include the age, the body mass index, and the ovarian reserve markers like the antral follicle count (AFC), the follicle stimulation hormone (FSH) and antimullerian hormone (AMH) serum levels. The investigators will also determine the number of oocytes retrieved and the metaphase two oocytes in both groups after IVF stimulation.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 42 Years

Healthy volunteers

Inclusion criteria

* Women aged \< 42 years old, with both ovaries present, undergoing a first or second IVF treatment due to male factor, tubal disease or previous failed intrauterine insemination (IUI).

Exclusion criteria

* Women diagnosed of polycystic ovary syndrome according to Rotterdam criteria, endometriosis stage III-IV, or previous pelvic inflammatory disease.

Design outcomes

Primary

Measure	Time frame	Description
AMH levels produced by granulosa cells	day 1	AMH levels (ng/mL) as well as AFC in both ethnic groups.

Secondary

Measure	Time frame	Description
Number of oocytes	day 1	The number of oocytes retrieved as well as the mature oocytes after IVF ovarian stimulation

Outcome results